⊕ Medical information · we may earn if you start a program · editorial independence

Phase 3 Updated May 2026

Retatrutide

Investigational (Eli Lilly)

Triple agonist (GIP, GLP-1, glucagon) in Phase 3 trials — not yet FDA-approved.

Avg. weight loss ~24% (Ph2)

Dose range TBD

Cadence Weekly

How it works

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. The glucagon pathway adds energy expenditure benefits on top of appetite suppression. Phase 2 data showed approximately 24% weight loss at 48 weeks, but the drug is not yet FDA-approved.

FAQ — Common questions about Retatrutide

What is retatrutide?

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials and is not yet FDA-approved.

When will retatrutide be available?

Retatrutide is in Phase 3 clinical trials. If approved, it could be available by late 2026 or 2027. We will update our reviews as new data becomes available.

⊕ FAQPage schema · injected at build time

Find the right provider for Retatrutide. Compare pricing, clinician quality, and shipping across all reviewed providers.

View full comparison →